keyword
MENU ▼
Read by QxMD icon Read
search

Vva

keyword
https://www.readbyqxmd.com/read/28419068/visual-improvements-in-vaginal-mucosa-correlate-with-symptoms-of-vva-data-from-a-double-blind-placebo-controlled-trial
#1
James A Simon, David F Archer, Risa Kagan, Brian Bernick, Shelli Graham, Ginger D Constantine, Sebastian Mirkin
OBJECTIVE: To evaluate the response of the vaginal mucosa with TX-004HR and its correlation with vulvar and vaginal atrophy (VVA) symptoms, and whether visual examination is a useful measure for assessing VVA. METHODS: REJOICE was a 12-week, phase 3, multicenter, randomized, double-blind, placebo-controlled study of a vaginal, muco-adhesive, 17β-estradiol softgel capsule (TX-004HR 4, 10, and 25 μg) in postmenopausal women with VVA and moderate-to-severe dyspareunia...
April 17, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28398023/clinical-profile-of-women-with-vva-who-are-not-candidates-for-local-vaginal-oestrogen-therapy
#2
Rossella E Nappi, Filippo Murina, Giuseppina Perrone, Paola Villa, Nicoletta Biglia
Vulvar and vaginal atrophy (VVA) is a chronic medical condition in postmenopausal women, which is predominantly due to a permanent cessation of ovarian oestrogen production. Current available treatment options for VVA are over-the-counter (OTC) symptomatic relief products or local oestrogen therapy (LET) aiming to treat this underlying atrophic condition. Recent surveys indicated that these products decrease sexual spontaneity, are messy and indiscrete. Ospemifene is an oral daily drug, which has proven to treat vaginal dryness and dyspareunia effectively...
April 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28388560/galnt6-expression-enhances-aggressive-phenotypes-of-ovarian-cancer-cells-by-regulating-egfr-activity
#3
Tzu-Chi Lin, Syue-Ting Chen, Min-Chuan Huang, John Huang, Chia-Lang Hsu, Hsueh-Fen Juan, Ho-Hsiung Lin, Chi-Hau Chen
Ovarian cancer is the most lethal of the gynecologic malignancies. N-acetylgalactosaminyltransferase 6 (GALNT6), an enzyme that mediates the initial step of mucin type-O glycosylation, has been reported to regulate mammary carcinogenesis. However, the expression and role of GALNT6 in ovarian cancer are still unclear. Here we showed that high GALNT6 expression correlates with increased recurrence, lymph node metastasis, and chemoresistance in ovarian endometrioid and clear cell carcinomas; and higher GALNT6 levels are significantly associated with poorer patient survivals...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28364869/a-vaginal-estradiol-softgel-capsule-tx-004hr-has-negligible-to-very-low-systemic-absorption-of-estradiol-efficacy-and-pharmacokinetic-data-review
#4
REVIEW
James A Simon, David F Archer, Ginger D Constantine, James H Pickar, Julia M Amadio, Brian Bernick, Shelli Graham, Sebastian Mirkin
This paper reviews the efficacy, safety, and systemic absorption of estradiol with TX-004HR, an investigational, low-dose 17β-estradiol vaginal softgel capsule, designed to treat vulvar and vaginal atrophy (VVA) in postmenopausal women, with an improved user experience. In phase 2 (NCT02449902) and phase 3 REJOICE (NCT02253173) studies, TX-004HR significantly improved the proportions of vaginal superficial and parabasal cells and vaginal pH, and in the phase 3 study decreased the severity of dyspareunia, vaginal dryness, and vulvar and/or vaginal itching or irritation...
May 2017: Maturitas
https://www.readbyqxmd.com/read/28355090/consistency-of-effect-with-a-low-dose-estradiol-vaginal-capsule-tx-004hr-evaluating-improvement-in-vaginal-physiology-and-moderate-to-severe-dyspareunia-in-subgroups-of-postmenopausal-women
#5
Ginger D Constantine, Celine Bouchard, James H Pickar, David F Archer, Shelli Graham, Brian Bernick, Sebastian Mirkin
BACKGROUND: The 12-week, randomized, double-blind, placebo-controlled, multicenter, phase 3 REJOICE trial demonstrated that TX-004HR, an investigational, applicator-free, low-dose vaginal softgel capsule containing solubilized 17β-estradiol, effectively and rapidly treats symptoms of vulvar and vaginal atrophy (VVA) with negligible to very low systemic absorption. The aim of this analysis was to assess whether the efficacy of TX-004HR varies with age, body mass index (BMI), uterine status, pregnancy status, and vaginal delivery...
March 29, 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28323042/comparison-of-intravaginal-0-5-prasterone-0-3mg-conjugated-estrogens-and-10%C3%AE-g-estradiol-on-estrogen-related-symptoms-of-vulvovaginal-atrophy
#6
REVIEW
David F Archer, Fernand Labrie, Marlene Montesino, Céline Martel
The objective is to compare the effect of intravaginal dehydroepiandrosterone (DHEA, prasterone), conjugated equine estrogens (CEE) and estradiol (E2) on moderate to severe dyspareunia and/or vaginal dryness. In a review of available data, independent prospective, randomized, double-blind and placebo-controlled Phase III 12-week clinical trials involved daily administration of 6.5mg (0.50%) prasterone, daily (21days on/7days off) 0.3mg CEE, twice weekly 0.3mg CEE or 10 μg E2 daily for 2 weeks followed by twice weekly for 10 weeks...
March 17, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/28277131/macro-regional-variation-in-attitudes-toward-and-experiences-of-vulvar-and-vaginal-atrophy-among-italian-post-menopausal-women-a-post-hoc-analysis-of-revive-survey-data
#7
Rossella E Nappi, Martire Particco, Nicoletta Biglia, Angelo Cagnacci, Costantino Di Carlo, Stefano Luisi, Anna Maria Paoletti
Italian participants in the European REVIVE survey reported that vaginal and vulvar atrophy (VVA) impaired various aspects of their lives, notably the ability to enjoy sex. The aim of the present study was to explore regional differences in knowledge, experiences, and treatment of VVA in the Italian REVIVE sample (n = 1000), which was analyzed according to region of residence. While many respondents were unfamiliar with the VVA condition, most could relate their VVA symptoms to the menopause. The rate of diagnosis of VVA was twice as high in Central Italy as in the North-East...
February 21, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28275615/cannulation-techniques-for-extracorporeal-life-support
#8
REVIEW
Evgeny Pavlushkov, Marius Berman, Kamen Valchanov
The article reviews cannulation strategy for different modes of extracorporeal life support. Technical aspects, pitfalls and complications are discussed for central and peripheral extracorporeal membrane oxygenation (VA, VV, VAV, VVA), biventricular assist device support and extracorporeal CO2 removal.
February 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28267367/systematic-indirect-comparison-of-ospemifene-versus-local-estrogens-for-vulvar-and-vaginal-atrophy
#9
N Bruyniks, N Biglia, S Palacios, A O Mueck
In the absence of a direct head-to-head study, we performed an indirect historical comparison of ospemifene 60 mg (Senshio(®)) vs. local vaginal estrogens in moderate or severe vulvar and vaginal atrophy (VVA). A literature search was carried out of clinical efficacy/safety trials of local vaginal estrogens in VVA approved in Europe. For efficacy comparison, studies had to be placebo-controlled and of 12 weeks' duration. For safety comparison, studies had to be ≥40 weeks' duration. Efficacy endpoints were the difference between active and placebo in change from baseline to week 12 for symptoms, vaginal pH, and maturation value (MV)...
March 7, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28202320/the-women-s-empower-survey-identifying-women-s-perceptions-on-vulvar-and-vaginal-atrophy-and-its-treatment
#10
Sheryl A Kingsberg, Michael Krychman, Shelli Graham, Brian Bernick, Sebastian Mirkin
INTRODUCTION: Vulvar and vaginal atrophy (VVA) affects up to two thirds of postmenopausal women, but most symptomatic women do not receive prescription therapy. AIM: To evaluate postmenopausal women's perceptions of VVA and treatment options for symptoms in the Women's EMPOWER survey. METHODS: The Rose Research firm conducted an internet survey of female consumers provided by Lightspeed Global Market Insite. Women at least 45 years of age who reported symptoms of VVA and residing in the United States were recruited...
February 12, 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28202319/the-women-s-empower-survey-women-s-knowledge-and-awareness-of-treatment-options-for-vulvar-and-vaginal-atrophy-remains-inadequate
#11
Michael Krychman, Shelli Graham, Brian Bernick, Sebastian Mirkin, Sheryl A Kingsberg
INTRODUCTION: Postmenopausal women's knowledge about vulvar and vaginal atrophy (VVA) and available treatment options has historically been inadequate. Recent direct-to-consumer marketing and educational efforts would have been expected to increase awareness and treatment options. AIM: To compare results of the Women's EMPOWER survey with other available VVA surveys to assess progress in women's understanding and approaches to treatment of VVA. METHODS: The Women's EMPOWER survey, an internet-based survey of US women with VVA symptoms, assessed women's awareness of VVA and their behaviors and attitudes associated with symptom treatment...
March 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28195995/patient-acceptability-and-satisfaction-with-a-low-dose-solubilized-vaginal-estradiol-softgel-capsule-tx-004hr
#12
Sheryl A Kingsberg, Robin Kroll, Irwin Goldstein, Harvey Kushner, Brian Bernick, Shelli Graham, Sebastian Mirkin, Ginger D Constantine
OBJECTIVE: TX-004HR is an investigational, muco-adhesive, vaginal, softgel capsule containing low-dose, solubilized, 17β-estradiol designed to treat postmenopausal vulvar and vaginal atrophy (VVA) and improve user experience without an applicator and less mess. METHODS: As part of the 12-week, placebo-controlled, double-blind, phase 3 REJOICE trial evaluating the efficacy/safety of 4-, 10-, and 25-μg TX-004HR in 764 postmenopausal women with VVA, a five-question product survey was administered...
February 13, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28122807/the-number-of-chandelier-and-basket-cells-are-differentially-decreased-in-prefrontal-cortex-in-autism
#13
Jeanelle Ariza, Haille Rogers, Ezzat Hashemi, Stephen C Noctor, Verónica Martínez-Cerdeño
An interneuron alteration has been proposed as a source for the modified balance of excitation / inhibition in the cerebral cortex in autism. We previously demonstrated a decreased number of parvalbumin (PV)-expressing interneurons in prefrontal cortex in autism. PV-expressing interneurons include chandelier (Ch) and basket (Bsk) cells. We asked whether the decreased PV+ interneurons affected both Ch cells and Bsk cells in autism. The lack of single markers to specifically label Ch cells or Bsk cells presented an obstacle for addressing this question...
November 24, 2016: Cerebral Cortex
https://www.readbyqxmd.com/read/28110670/galnt6-stabilizes-grp78-protein-by-o-glycosylation-and-enhances-its-activity-to-suppress-apoptosis-under-stress-condition
#14
Jiaying Lin, Suyoun Chung, Koji Ueda, Koichi Matsuda, Yusuke Nakamura, Jae-Hyun Park
We previously reported that overexpression of an O-type glycosyltransferase, GALNT6 (polypeptide N-acetylgalactosaminyltransferase 6) played critical roles in mammary carcinogenesis. To further investigate the biological function of GALNT6, we screened a substrate protein(s) of GALNT6 using a VVA (Vicia villosa agglutinin) lectin (specific to GalNAc-Ser/Thr) pull-down method followed by mass spectrometry analysis. Here we report GRP78 (glucose-regulated protein 78, also known as HSPA5, heat shock 70 kDa protein 5), which is highly expressed in cancer cells and indicated to play important roles in various cellular processes including ER (endoplasmic reticulum) stress and autophagy, as a novel substrate of GALNT6...
January 2017: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/28064523/iranian-postmenopausal-women-s-experiences-of-treatment-of-symptomatic-vulvovaginal-atrophy
#15
E Fooladi, M Deldar, F Mohammadzadeh, E Ahmadnia, S Khani, Z Ghanbari
OBJECTIVES: Our aim was to explore the experiences of Iranian postmenopausal women who sought medical help for their symptomatic vulvovaginal atrophy (VVA). METHODS: Five focus group discussions (FGDs) were conducted. Participants had to be postmenopausal; had bothersome symptoms of VVA for which they came to the clinic; had previously sought medical help for their VVA; and had confirmed physical signs of VVA upon examination by a gynecologist. RESULTS: Twenty-five women, aged 49-60 years participated in the five FGDs...
February 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28056209/fractional-co2-laser-from-skin-rejuvenation-to-vulvo-vaginal-reshaping
#16
Maurizio Filippini, Ester Del Duca, Francesca Negosanti, Diletta Bonciani, Luca Negosanti, Mario Sannino, Giovanni Cannarozzo, Steven Paul Nisticò
BACKGROUND: The CO2 laser has become the gold standard treatment in dermatologic surgery for the treatment of a large number of skin and mucosal lesions. The introduction of the fractional micro-ablative technology represented an integration to the ablative resurfacing technique, reducing the healing time and the side effects. OBJECTIVE: Vaginal rejuvenation performed with this technique is a minimally invasive procedure that stimulates internal tissues of the female lower genital tract to regenerate the mucosa, improving tissue trophism and restoring the correct functionality...
March 2017: Photomedicine and Laser Surgery
https://www.readbyqxmd.com/read/28042734/vulvar-and-vaginal-atrophy-as-viewed-by-the-spanish-revive-participants-symptoms-management-and-treatment-perceptions
#17
S Palacios, M J Cancelo, C Castelo Branco, P Llaneza, F Molero, R Sanchez Borrego
OBJECTIVES: To gain a deeper comprehension of current vulvovaginal atrophy (VVA) knowledge among Spanish postmenopausal women. METHODS: An online survey (REVIVE) was conducted in four European countries with an overall sample of 768 participants included in Spain. Perceptions, experiences and needs of Spanish postmenopausal women in terms of sexual and vaginal health were reported. RESULTS: Vaginal dryness was the most common VVA symptom in Spain (81%)...
February 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/27934828/generation-and-characterisation-of-monoclonal-antibodies-specific-to-avian-influenza-h7n9-haemagglutinin-protein
#18
A Malik, Vva Mallajosyula, N N Mishra, A P Arukha, R Varadarajan, S K Gupta
INTRODUCTION: Emerging virulent strains of influenza virus pose a serious public health threat with potential pandemic consequences. A novel avian influenza virus, H7N9, breached the species barrier from infected domestic poultry to humans in 2013 in China. Since then, it has caused numerous infections in humans with a close contact to poultry. MATERIALS AND METHODS: In this study, we describe the preliminary characterisation of five murine monoclonal antibodies (MAbs) developed against recombinant haemagglutinin (rHA) protein of avian H7N9 A/Anhui/1/2013 virus by their Western blot and enzyme-linked immunosorbent assay (ELISA) reactivity and binding affinity...
October 2016: Indian Journal of Medical Microbiology
https://www.readbyqxmd.com/read/27896230/evaluation-of-symptoms-and-prevention-of-cancer-in-menopause-the-value-of-vulvar-exam
#19
A R Palumbo, C Fasolino, G Santoro, V Gargano, M Rinaldi, B Arduino, M Belli, M Guida
Vulvar and vaginal atrophy (VVA), is a chronic medical condition experienced by postmenopausal women, with prevalence estimated ranging from 10% to 50% [1]. VVA is characterized by a constellation of symptoms, that may affect daily activities, sexuality, relationships, and quality of life [3]. Early recognition and effective treatment of VVA may enhance sexual health and the quality of life of women and their partners. Some vulvar conditions such as lichen sclerosus are more prevalent in the postmenopausal years...
November 2016: Translational Medicine @ UniSa
https://www.readbyqxmd.com/read/27831658/postmenopausal-vulvovaginal-atrophy-vva-is-positively-improved-by-topical-hyaluronic-acid-application-a-prospective-observational-study
#20
M Origoni, C Cimmino, G Carminati, E Iachini, C Stefani, S Girardelli, S Salvatore, M Candiani
OBJECTIVE: To evaluate the effectiveness of a topical vaginal preparation containing hyaluronic acid in controlling signs and symptoms correlated with postmenopausal vulvovaginal atrophy (VVA). PATIENTS AND METHODS: A prospective, observational study has been performed at the Obstetrics and Gynecology Department of the Vita Salute San Raffaele University of Milan, Italy. Forty-six (46) consecutive postmenopausal women complaining of genital discomfort due to postmenopausal estrogen lack have been enrolled...
October 2016: European Review for Medical and Pharmacological Sciences
keyword
keyword
5071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"